Sanglard D, Kuchler K, Ischer F, Pagani J L, Monod M, Bille J
Institut de Microbiologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Antimicrob Agents Chemother. 1995 Nov;39(11):2378-86. doi: 10.1128/AAC.39.11.2378.
Azole antifungal agents, and especially fluconazole, have been used widely to treat oropharyngeal candidiasis in patients with AIDS. An increasing number of cases of clinical resistance against fluconazole, often correlating with in vitro resistance, have been reported. To investigate the mechanisms of resistance toward azole antifungal agents at the molecular level in clinical C. albicans isolates, we focused on resistance mechanisms related to the cellular target of azoles, i.e., cytochrome P450(14DM) (14DM) and those regulating the transport or accumulation of fluconazole. The analysis of sequential isogenic C. albicans isolates with increasing levels of resistance to fluconazole from five AIDS patients showed that overexpression of the gene encoding 14DM either by gene amplification or by gene deregulation was not the major cause of resistance among these clinical isolates. We found, however, that fluconazole-resistant C. albicans isolates failed to accumulate 3H-labelled fluconazole. This phenomenon was reversed in resistant cells by inhibiting the cellular energy supply with azide, suggesting that resistance could be mediated by energy-requiring efflux pumps such as those described as ATP-binding cassette (ABC) multidrug transporters. In fact, some but not all fluconazole-resistant clinical C. albicans isolates exhibited up to a 10-fold relative increase in mRNA levels for a recently cloned ABC transporter gene called CDR1. In an azole-resistant C. albicans isolate not overexpressing CDR1, the gene for another efflux pump named BENr was massively overexpressed. This gene was cloned from C. albicans for conferring benomyl resistance in Saccharomyces cerevisiae. Therefore, at least the overexpression or the deregulation of these two genes potentially mediates resistance to azoles in C. albicans clinical isolates from AIDS patients with oropharyngeal candidiasis. Involvement of ABC transporters in azole resistance was further evidenced with S. cerevisiae mutants lacking specific multidrug transporters which were rendered hypersusceptible to azole derivatives including fluconazole, itraconazole, and ketoconazole.
唑类抗真菌药,尤其是氟康唑,已被广泛用于治疗艾滋病患者的口腔念珠菌病。越来越多对氟康唑临床耐药的病例被报道,且常常与体外耐药相关。为了在分子水平上研究临床白色念珠菌分离株对唑类抗真菌药的耐药机制,我们聚焦于与唑类药物细胞靶点相关的耐药机制,即细胞色素P450(14DM)以及那些调节氟康唑转运或蓄积的机制。对来自5例艾滋病患者的对氟康唑耐药性逐渐增强的一系列同基因白色念珠菌分离株进行分析发现,编码14DM的基因通过基因扩增或基因去调控而过度表达并非这些临床分离株耐药的主要原因。然而,我们发现对氟康唑耐药的白色念珠菌分离株无法蓄积3H标记的氟康唑。通过用叠氮化物抑制细胞能量供应,耐药细胞中的这种现象得以逆转,这表明耐药可能由需要能量的外排泵介导,比如那些被描述为ATP结合盒(ABC)多药转运蛋白的泵。事实上,一些(但并非全部)对氟康唑耐药的临床白色念珠菌分离株,对于一个最近克隆的名为CDR1的ABC转运蛋白基因,其mRNA水平相对增加了高达10倍。在一株不过度表达CDR1的唑类耐药白色念珠菌分离株中,另一个名为BENr的外排泵基因大量过度表达。该基因是从白色念珠菌中克隆出来的,用于在酿酒酵母中赋予对苯菌灵的抗性。因此,至少这两个基因的过度表达或去调控可能介导了艾滋病患者口腔念珠菌病临床分离株中白色念珠菌对唑类药物的耐药性。缺乏特定多药转运蛋白的酿酒酵母突变体对包括氟康唑、伊曲康唑和酮康唑在内的唑类衍生物变得高度敏感,这进一步证明了ABC转运蛋白与唑类耐药有关。